ProCE Banner Activity

Is Immune Modulation the Future of Therapy in Follicular Lymphoma?

Clinical Thought
Insights on the utility of immunotherapy in follicular lymphoma from recent clinical trials.

Released: February 11, 2015

Expiration: February 10, 2016

No longer available for credit.

Share

Faculty

Andrew D. Zelenetz

Andrew D. Zelenetz, MD, PhD

Associate Professor, Department of Medicine
Cornell University Medical College
Chief, Lymphoma Service
Memorial Sloan-Kettering Cancer Center
New York, New York

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Gilead

Faculty Disclosure

Primary Author

Andrew D. Zelenetz, MD, PhD

Associate Professor, Department of Medicine
Cornell University Medical College
Chief, Lymphoma Service
Memorial Sloan-Kettering Cancer Center
New York, New York

Andrew D. Zelenetz, MD, PhD, has disclosed that he has received consulting fees from Adaptive Biotechnology, Amgen, Celgene, Genentech/Roche, Gilead Sciences, GlaxoSmithKline, Hospira, Janssen, Nanostring Technologies, Novartis, Portola Pharmaceuticals, and Takeda Pharma; has received funds for research support from Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen, and Roche; and has served on the data monitoring committee for Boehringer Ingelheim.